Phase 1 Trial of ALRN-6924, a Dual Inhibitor of MDMX and MDM2, in Patients with Solid Tumors and Lymphomas Bearing Wild-Type TP53

出版年份 2021 全文链接

标题

作者

关键词

出版物

Volume -, Issue -, Pages clincanres.0715.2021

出版商

American Association for Cancer Research (AACR)

发表日期

2021-07-23

DOI

10.1158/1078-0432.ccr-21-0715

Discuss science. Find collaborators. Network.

Join a conversation

The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.

Get Started